Manuscripts
Showing 1554 manuscripts.
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger than 3 Years.
Citation
EV Capparelli, CB Moore, P Jean-Philippe, SA Spector, N Chakhtoura, A Benns, B Zimmer, L Purdue, C Jackson, C Wallis, JL Libous, EG Chadwick, IMPAACT P1070 Study Team, M Bwakura Dangarembizi, P Samson. Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger than 3 Years.. Journal of Acquired Immune Deficiency Syndromes. 2019. 81: 473-480. PMID: 31241542Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1070
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
Citation
RS Mwiru, A Mwatha, AM Young, D Moodley, HM Coovadia, L Staranix-Chibanda, K Manji, Y Maldonado, P Richardson, P Andrew, K George, W Fawzi, MG Fowler, C Onyango-Makumbi, AH Owora. Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 377-385. PMID: 31567725Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Citation
Edward P Acosta, Edmund Capparelli, Anne Chain, Hedy Teppler, Betsy Smith, Jos Lommerse, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team, Diana F Clarke, Mark Mirochnick. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 392-398. PMID: 31658182Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1110
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis
Citation
EP Acosta, J Moye, E Townley, S Bradford, L Marillo, K Denson, L Hovind, T Sise, H Teppler, SR Mathiba, A Hesseling, MF Cotton, P Krogstad, IMPAACT P1101 Team, T Meyers, P Samson. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019. 15: 2197-2203. PMID: 31689263Year
2019
Journal
AIDS
Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men
Citation
Sean S Brummel, Risa M Hoffman, Jonathan Z Li, Patricia M Flynn, Taha E Taha, Anne Coletti, Mary Glenn Fowler, Ronald J Bosch, Rajesh T Gandhi, Karin L Klingman, James A McIntyre, Judith S Currier, Catherine N Le, Paul Britto. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men. AIDS. 2019. 33: 2149-2156. PMID: 31373919Year
2019
Journal
AIDS
Study
1077HS
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis
Citation
Terry Fenton, Dhayendre Moodley, Shilpa Naik, Clemensia Nakabiito, Lee Fairlie, Mary Glenn Fowler, Jeffrey S A Stringer, Benjamin H Chi, Kartik Kailas Venkatesh, Mona Farhad. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis. AIDS. 2019. 33: 2403-2413. PMID: 31764105Year
2019
Journal
AIDS
Study
1077BF, 1077FF
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Citation
T Kerbusch, H Merdjan, H Witjes, H Teppler, M Mirochnick, EP Acosta, L Wenning, S Nachman, A Chain, J Lommerse, D Clarke. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. CPT: pharmacometrics & systems pharmacology. 2019. 8: 643-653. PMID: 31215170Year
2019
Journal
CPT: pharmacometrics & systems pharmacology
Study
P1066
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
Citation
Angela Colbers, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, José Moltó, Mark Mirochnick, Mats O Karlsson, David M Burger, Stein Schalkwijk, Rob Ter Heine. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy. 2019. 74: 1348-1356. PMID: 30715324Year
2019
Journal
Journal of Antimicrobial Chemotherapy
Study
P1026S
Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial
Citation
David E Shapiro, Patricia M Flynn, Taha E Taha, Tichaona Vhembo, Mae Cababasay, Mary Glenn Fowler, Raziya Bobat, Lynne Mofenson, Blandina Mmaga, Mazensia Owor, Maysseb Masenya, Susan Fiscus, Mandisa Nyati, Lynda Stranix-Chibanda, Gerhard Theron, Anna Coutsoudis, Helen Mulenga, Devasena Gnanashanmugam, Nahida Chakhtoura, The PROMISE Team, Katie McCarthy, Cornelius Mukuzunga, Bonus Makanani, Dhayendre Moodley, Teacler Nematadzira, Bangini Kusakara, Sandesh Patil. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. Journal of Acquired Immune Deficiency Syndromes. 2018. 77: 383-392. PMID: 29239901Year
2018
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077BF